Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study

Table 1 Clinical characteristics of patients who received one-shot CDDP via HAI plus RT

Characteristics	Median (range) or number of patients
Age (years)	69.5 (40–85)
Gender (male/female)	28/4
ECOG-Performance Status (0/1)	25/7
Etiology (HBV/HCV/HBV + HCV/other)	9/10/1/12
Total bilirubin (mg/dL)	0.9 (0.4–1.5)
Albumin (g/dL)	3.5 (2.6–4.6)
Prothrombin consumption test (%)	86.0 (6.2–111)
Child–Pugh score (5/6/7)	9/10/13
ALBI score	− 2.17 (− 3.24– − 1.28)
mALBI grade (1/2a/2b/3)	5/7/19/1
Size of liver tumor (mm)	103.2 (36–185)
Number of intrahepatic tumors (< 4/ ≥ 4)	18/14
Relative tumor volume in the liver (< 50%/ ≥ 50%)	19/13
Vp (3/4)	13/15
Vv (0/1/2/3)	27/1/1/3
Extrahepatic spread (without/with)	22/10
HCC stage (III/IVa/IVb)^a	4/6/22
BCLC stage (A/B/C)	0/0/32
Alpha-fetoprotein (ng/mL)	713.2 (1.3–3,686,000)
Des-γ-carboxy prothrombin (mAU/mL)	10,039 (36–327,600)
Additional systemic therapy (with/without)	23/9

The clinical characteristics of the HCC patients with MVI who received one-shot CDDP chemotherapy via HAI plus RT. HCC hepatocellular carcinoma; MVI macrovascular invasion; HAI hepatic arterial infusion; CDDP cisplatin; HAI hepatic arterial infusion; RT radiation therapy; ECOG-Performance Status Eastern Cooperative Oncology Group Performance Status; HBV hepatitis B virus; HCC hepatocellular carcinoma; HCV hepatitis C virus; ALBI score = log₁₀([total-bilirubin(mg/dL)]*17.1*0.66 − [albumin(g/dL)]*10*0.085; mALBI grade 1: 2a: 2b: 3 = ALBI score ≤ − 2.6: > − 2.6 to < − 2.27: ≥ − 2.27 to ≤ − 1.39: > − 1.39; Vp portal vein invasion; Vv venous invasion; BCLC stage Barcelona Clinic liver cancer stage
^aAccording to the Liver Cancer Study Group of Japan

ISSN: 1471-230X